BioCryst Pharmaceuticals traded at $10.74 this Thursday February 2nd, increasing $0.22 or 2.09 percent since the previous trading session. Looking back, over the last four weeks, BioCryst Pharmaceuticals gained 6.20 percent. Over the last 12 months, its price fell by 28.16 percent. Looking ahead, we forecast BioCryst Pharmaceuticals to be priced at 10.23 by the end of this quarter and at 9.26 in one year, according to Trading Economics global macro models projections and analysts expectations.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
Chugai Pharma 3,377.00 81.00 2.46% -15.15%
Daiichi Sankyo 4,061.00 21.00 0.52% 75.80%
Alnylam Pharmaceuticals 229.75 4.84 2.15% 61.22%
BioCryst Pharmaceuticals 10.74 0.22 2.09% -28.16%
DBV Technologies 1.40 -0.05 -3.45% -8.50%
Enanta Pharmaceuticals 52.75 0.84 1.62% -9.88%
Gilead Sciences 84.43 3.04 3.74% 29.12%
GlaxoSmithKline 1,442.80 15.40 1.08% -11.76%
Glaxosmithkline 35.44 0.31 0.87% -21.11%
Incyte Corp 84.45 -0.04 -0.05% 15.61%
Ionis Pharmaceuticals 41.20 1.17 2.92% 32.60%
Intra Cellular Therapies 49.74 1.92 4.02% 7.43%
Karyopharm Therapeutics 3.51 0.17 5.09% -61.17%
Mirati Therapeutics 54.26 1.57 2.98% -53.96%
Neurocrine Biosciences 108.00 -2.22 -2.01% 35.76%
Novavax 12.01 0.78 6.95% -86.43%
PTC Therapeutics 47.36 -0.01 -0.02% 18.52%
Ultragenyx Pharmaceutical 47.34 2.10 4.64% -29.98%
Regeneron Pharmaceuticals 768.86 17.66 2.35% 23.42%
Roche Holding 283.30 9.45 3.45% -17.94%
Sarepta Therapeutics 120.25 -2.11 -1.72% 73.07%
Vertex Pharmaceuticals 304.22 0.44 0.14% 25.73%

Indexes Price Day Year
USND 12049 -151.77 -1.24% -14.53%
US2000 1987 -14.71 -0.73% -0.79%

BioCryst Pharmaceuticals
BioCryst Pharmaceuticals, Inc. discovers oral and small-molecule medicines that treat rare diseases in which unmet medical needs exist and an enzyme plays the key role in the biological pathway of the disease. ORLADEYO (berotralstat) is an oral, once-daily therapy that is approved in the United States, the European Union, Japan, and the United Kingdom for the prevention of hereditary angioedema attacks in adults and pediatric patients 12 years and older. The Company has several ongoing development programs, including BCX9930, an oral Factor D inhibitor for the treatment of complement-mediated diseases; BCX9250, an activin receptor-like kinase-2 inhibitor for the treatment of fibrodysplasia ossificans progressiva, and galidesivir, an antiviral drug for Marburg virus disease and Yellow Fever. RAPIVAB (peramivir injection) is a viral neuraminidase inhibitor for the treatment of influenza, has received regulatory approval in the United States, Canada, Australia, Japan, Taiwan and Korea.